Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SynAct Pharma AB ( (SE:SYNACT) ) has shared an update.
SynAct Pharma has released its annual results for January to December 2025, providing an overview of its financial development, research and development progress, and corporate activities. The report highlights significant events in the fourth quarter, CEO commentary, and details on the company’s share performance, signaling an ongoing focus on advancing its inflammatory disease pipeline and informing stakeholders of its operational status.
The publication of this comprehensive interim report underscores SynAct Pharma’s efforts to maintain transparency with investors and other stakeholders as it progresses through clinical development. By outlining its R&D initiatives and financial position, the company reinforces its strategic focus on melanocortin-based therapies and its intention to strengthen its position in the inflammatory disease biotech space.
The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK22.00 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company based in Lund, Sweden, specializing in research and development of therapies targeting inflammatory diseases. The company focuses on resolving inflammation through melanocortin biology, positioning itself within the immunology and inflammation segment of the biotech industry.
Average Trading Volume: 135,123
Technical Sentiment Signal: Sell
Current Market Cap: SEK993M
For a thorough assessment of SYNACT stock, go to TipRanks’ Stock Analysis page.